Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)

NCT01091142 is registered in ClinicalTrials.gov with Neuraltus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01091142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01091142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-Ascending-Dose Safety and Tolerability Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Lead sponsor
Neuraltus Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2010
Completion date
Not reported
Enrollment
56 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis